Merrimack Debuts New Website

24 Sep, 2015, 16:00 ET from Merrimack

CAMBRIDGE, Mass., Sept. 24, 2015 /PRNewswire/ -- Merrimack (NASDAQ: MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and diagnostics, today announced the debut of its new website, www.merrimack.com. The company also announced it has adopted Merrimack as its brand name and "Cures are built" as its tagline.  

"We are pleased to announce the debut of our new website, which was designed to enhance the user experience, with easier navigation and a clearer presentation of Merrimack's broader capabilities. We aren't just developing new therapies to treat cancer, we're also identifying novel biomarkers and creating companion diagnostics to help ensure that cancer patients don't receive treatments unlikely to benefit them," said Bob Mulroy, Merrimack CEO. "With this new website we hope to convey our dedication to applying systems engineering to better understand the complex, multi-dimensional aspects of cancer."

As part of the new website, Merrimack presents cancer as "the ultimate engineering challenge" and provides information about the company's pipeline, clinical trials and integrated approach to bringing precision diagnostics together with new treatment regimens.

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. With five candidates in clinical trials, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Dana Robie Merrimack 617-441-7408 drobie@merrimack.com

Logo- http://photos.prnewswire.com/prnh/20150325/194550LOGO

 

SOURCE Merrimack



RELATED LINKS

http://www.merrimack.com